2024-02-13 09:04:41 ET
Summary
- Gilead Sciences' acquisition of CymaBay Therapeutics introduces seladelpar into its portfolio, expanding its presence in liver diseases.
- Seladelpar shows clinical promise for PBC, with significant improvements in key liver health markers and pruritus relief.
- Financially, the acquisition is earnings-neutral short term, with accretion expected post-2025, despite Gilead's significant debt.
- Recommendation: Hold Gilead shares, monitoring seladelpar's market integration and Gilead's financial management post-acquisition.
At a Glance
Read the full article on Seeking Alpha
For further details see:
CymaBay's Seladelpar Is A Solid, But Pricey, Addition To Gilead's Liver Franchise